TSE:4507Pharmaceuticals
Shionogi (TSE:4507) Valuation Check After XOCOVA Post Exposure COVID 19 Approval
Shionogi (TSE:4507) is back in focus after Japan approved an expanded indication for its anti SARS-CoV-2 drug XOCOVA for post-exposure prophylaxis of COVID-19, grounded in positive global Phase 3 data.
See our latest analysis for Shionogi.
The XOCOVA approval has arrived alongside other pipeline updates, and the share price has reflected this with a 19.97% 90 day share price return and a 51.24% 1 year total shareholder return, suggesting momentum has been building over time.
If you want to...